サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414320

変力薬の世界市場レポート 2024年

Inotropic Agents Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
変力薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

変力薬の市場規模は近年急速に拡大しています。2023年の23億2,000万米ドルから2024年には25億9,000万米ドルへと、CAGR11.2％で拡大します。過去に見られた拡大は、教育・啓発に重点を置いた取り組み、心臓治療の選択肢の拡大、より安全な薬剤の進歩、患者転帰の向上、規制当局の承認によるものです。

変力薬の市場規模は今後数年で急成長が見込まれます。2028年にはCAGR11.6％で40億1,000万米ドルに成長します。予測期間中に予想される成長は、心血管疾患の負担の増加、ドラッグデリバリーシステムの進歩、個別化医療アプローチの採用、研究資金の増加、併用療法に対する需要の高まりに関連しています。予測期間中に予想される顕著な動向には、患者教育・啓発のための取り組み、心筋症への戦略的取り組み、心不全管理の重視、併用療法の統合、安全性プロファイルの進歩などが含まれます。

変力薬市場は、心血管疾患（CVDs）の有病率の増加によって急成長を遂げています。心血管疾患には、血管系および心臓機能の障害が含まれます。変力薬は、心臓の収縮力と機能を強化し、心臓ショックに対処し、心拍数を減少させることにより、これらの疾患の治療に重要な役割を果たしています。心臓の収縮を強化するその能力は、血流の改善につながります。注目すべきことに、2022年10月、米国疾病予防管理センターは、2020年の死者数が697,000人であり、米国における主要な死因は心臓病であると報告しています。このことは、死亡者の約5人に1人が心臓病によるものであることから、相当な市場需要があることを裏付けています。さらに、米国心臓病学会（American College of Cardiology）は、脳卒中リスクが33.8％増加し、2025年から2060年までに1500万症例に達すると予測しており、心血管疾患の有病率上昇により変力薬市場をさらに促進しています。

変力薬市場の成長は、ヘルスケア支出の増加によっても後押しされると予想されます。ヘルスケア支出は、特定の制度や経済圏におけるヘルスケアサービスや関連活動への総支出を示し、イノベーション、研究開発、診断能力の向上、高度な心臓治療への幅広いアクセスを助長する環境を生み出します。注目すべき例は英国で、2020年から2021年にかけてヘルスケア支出は名目で9.4％、実質で9.7％増加しました。2021年のヘルスケア支出総額は3,672億5,000万米ドル（2,807億円）に達し、医薬品支出は518億4,000万米ドル（396億円）、予防医療支出は459億3,000万米ドル（351億円）と2020年の2倍以上に増加します。その結果、ヘルスケア支出の増加基調が変力薬市場成長の原動力となっています。

2023年の変力薬市場で最大の地域は北米でした。アジア太平洋は、変力薬の世界市場レポートにおいて予測期間中に最も急成長する地域となる見込みです。変力薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の変力薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 陽性変力薬
  • 陰性変力薬
  • その他
  • 世界の変力薬市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界の変力薬市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 心臓発作
  • 心不全
  • 狭心症
  • 不整脈
  • その他
  • 世界の変力薬市場、流通チャネル別セグメンテーション：、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • その他
  • 世界の変力薬市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 在宅ケア
  • 専門センター
  • その他

第7章 地域および国の分析

  • 世界の変力薬市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の変力薬市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 変力薬市場の競合情勢
  • 変力薬市場の企業プロファイル
    • Pfizer Inc.
    • GSK plc
    • Novartis AG
    • Mylan NV
    • Boehringer Ingelheim International GmbH

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11830

“Inotropic Agents Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inotropic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inotropic agents? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The inotropic agents market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Positive Inotropic Drugs; Negative Inotropic Drugs; Other Types
  • 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
  • 3) By Indication: Heart Attack; Heart Failure; Angina; Arrhythmia; Other Indications
  • 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels
  • 5) By End User: Hospital; Homecare; Specialty Centers; Other End Users
  • Companies Mentioned: Pfizer Inc.; GSK plc; Novartis AG; Mylan N.V.; Boehringer Ingelheim International GmbH
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Inotropic agents constitute a category of medications that impact the contractility of the heart muscle, serving as a treatment for conditions such as heart failure, where the heart struggles to pump a sufficient amount of blood to meet the body's requirements. These agents function by augmenting the strength and vigor of the heart's contractions, thereby enhancing blood flow to the organs and tissues of the body.

The primary classifications within the realm of inotropic agents encompass positive inotropic drugs, negative inotropic drugs, and others. Positive inotropic drugs are medications designed to amplify the contractility or force of contraction in the heart muscle. Administration methods include oral, parenteral, and other routes, with distribution channels spanning hospital pharmacies, retail pharmacies, and others. Their application extends to treating diverse conditions such as heart attack, heart failure, angina, arrhythmia, among others. The primary end-users comprise hospitals, homecare, specialty centers, and others.

The inotropic agents market research report is one of a series of new reports from The Business Research Company that provides inotropic agents market statistics, including inotropic agents industry global market size, regional shares, competitors with a inotropic agents market share, detailed inotropic agents market segments, market trends and opportunities, and any further data you may need to thrive in the inotropic agents industry. This inotropic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inotropic agents market size has grown rapidly in recent years. It will grow from $2.32 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The expansion witnessed in the historical period can be ascribed to initiatives focused on education and awareness, the broadening of cardiac treatment alternatives, the advancement of safer agents, enhanced patient outcomes, and regulatory approvals.

The inotropic agents market size is expected to see rapid growth in the next few years. It will grow to $4.01 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be linked to the escalating burden of cardiovascular diseases, progress in drug delivery systems, the adoption of a personalized medicine approach, a rise in research funding, and a heightened demand for combination therapies. Prominent trends expected in the forecast period encompass initiatives for patient education and awareness, a strategic focus on addressing cardiomyopathies, an emphasis on heart failure management, the integration of combination therapies, and advancements in safety profiles.

The inotropic agent market is experiencing a surge in growth, driven by the increasing prevalence of cardiovascular diseases (CVDs). Cardiovascular diseases encompass disorders of the vascular system and heart function. Inotropic agents play a crucial role in treating these conditions by enhancing heart contractility and function, addressing cardiac shock, and reducing heart rate. Their ability to strengthen heart contractions leads to improved blood flow. Notably, in October 2022, the Centers for Disease Control and Prevention reported heart diseases as the leading cause of death in the US, with 697,000 deaths in 2020. This underscores the substantial market demand, as approximately 1 in every 5 deaths resulted from heart disease. Moreover, the American College of Cardiology projected a 33.8 percent increase in stroke risk, reaching 15 million cases from 2025 to 2060, further propelling the inotropic agent market due to the escalating prevalence of cardiovascular diseases.

The growth of the inotropic agents market is also anticipated to be boosted by the rising healthcare expenditure. Healthcare expenditure, denoting the total spending on healthcare services and related activities within a specific system or economy, creates an environment conducive to innovation, research and development, improved diagnostic capabilities, and broader access to advanced cardiac care. A notable example is the UK, where healthcare spending increased by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. The total healthcare expenditure in 2021 amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion) and preventive care spending more than doubling from 2020 to $45.93 billion (£35.1 billion). Consequently, the upward trajectory of healthcare expenditures is a driving force behind the growth of the inotropic agents market.

A key trend in the inotropic agents market is the emphasis on drug approval. Major companies in the market are actively developing innovative products and drugs to maintain their market positions. For example, in April 2022, Bristol-Myers Squibb secured regulatory approval from the U.S. Food and Drug Administration for Camzyos™ (mavacamten), a medication designed to treat class II-III obstructive hypertrophic cardiomyopathy (HCM). This drug inhibits excessive heart muscle contraction by selectively targeting cardiac myosin, a protein involved in muscle contraction. The approval of such novel drugs contributes to the overall growth and dynamism of the inotropic agents market.

A notable trend in the market is drug patent approval, which serves as a strategy for major companies to sustain their market standing. In October 2022, Windtree Therapeutics, Inc. obtained a patent for istaroxime, a groundbreaking drug candidate with a unique dual mechanism of action for treating heart failure. Istaroxime represents a first-in-class investigational drug with a distinct dual mechanism of action, signifying a potential breakthrough in cardiovascular medicine and offering hope for improved patient outcomes.

In March 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation, completed the acquisition of Arena Pharmaceuticals Inc. for $6.7 billion. This strategic move by Pfizer aims to enhance cardiovascular treatments and capabilities, aligning with the company's mission to deliver important medicines to patients. Arena Pharmaceuticals, Inc., a biopharmaceutical company specializing in inotropic and cardiovascular drugs, adds significant value to Pfizer's portfolio through this acquisition.

Major companies operating in the inotropic agents market report are Pfizer Inc., GSK plc, Novartis AG, Mylan N.V., Boehringer Ingelheim International GmbH, AstraZeneca plc, Johnson & Johnson, Bayer AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Cipla Ltd., Eli Lilly And Company, Sanofi S.A., Baxter International Inc., Hikma Pharmaceuticals plc, Sun Pharmaceuticals Industries Ltd., Cadila Pharmaceuticals Ltd., AbbVie Inc., Allergan plc, Amgen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Fresenius Kabi AG, Genentech Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Regeneron Pharmaceuticals Inc., Roche Holding AG, BioNTech SE

North America was the largest region in the inotropic agents market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global inotropic agents market report during the forecast period. The regions covered in the inotropic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the inotropic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The inotropic agent market consists of sales of digoxin, dopamine, dobutamine, levosimendan, and milrinone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Inotropic Agents Market Characteristics

3. Inotropic Agents Market Trends And Strategies

4. Inotropic Agents Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Inotropic Agents Market Size and Growth

  • 5.1. Global Inotropic Agents Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Inotropic Agents Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Inotropic Agents Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Inotropic Agents Market Segmentation

  • 6.1. Global Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Positive Inotropic Drugs
  • Negative Inotropic Drugs
  • Other Types
  • 6.2. Global Inotropic Agents Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Routes Of Administration
  • 6.3. Global Inotropic Agents Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Heart Attack
  • Heart Failure
  • Angina
  • Arrhythmia
  • Other Indications
  • 6.4. Global Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other Distribution Channels
  • 6.5. Global Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital
  • Homecare
  • Specialty Centers
  • Other End Users

7. Inotropic Agents Market Regional And Country Analysis

  • 7.1. Global Inotropic Agents Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Inotropic Agents Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Inotropic Agents Market

  • 8.1. Asia-Pacific Inotropic Agents Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Inotropic Agents Market

  • 9.1. China Inotropic Agents Market Overview
  • 9.2. China Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Inotropic Agents Market

  • 10.1. India Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Inotropic Agents Market

  • 11.1. Japan Inotropic Agents Market Overview
  • 11.2. Japan Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Inotropic Agents Market

  • 12.1. Australia Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Inotropic Agents Market

  • 13.1. Indonesia Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Inotropic Agents Market

  • 14.1. South Korea Inotropic Agents Market Overview
  • 14.2. South Korea Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Inotropic Agents Market

  • 15.1. Western Europe Inotropic Agents Market Overview
  • 15.2. Western Europe Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Inotropic Agents Market

  • 16.1. UK Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Inotropic Agents Market

  • 17.1. Germany Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Inotropic Agents Market

  • 18.1. France Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Inotropic Agents Market

  • 19.1. Italy Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Inotropic Agents Market

  • 20.1. Spain Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Inotropic Agents Market

  • 21.1. Eastern Europe Inotropic Agents Market Overview
  • 21.2. Eastern Europe Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Inotropic Agents Market

  • 22.1. Russia Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Inotropic Agents Market

  • 23.1. North America Inotropic Agents Market Overview
  • 23.2. North America Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Inotropic Agents Market

  • 24.1. USA Inotropic Agents Market Overview
  • 24.2. USA Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Inotropic Agents Market

  • 25.1. Canada Inotropic Agents Market Overview
  • 25.2. Canada Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Inotropic Agents Market

  • 26.1. South America Inotropic Agents Market Overview
  • 26.2. South America Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Inotropic Agents Market

  • 27.1. Brazil Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Inotropic Agents Market

  • 28.1. Middle East Inotropic Agents Market Overview
  • 28.2. Middle East Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Inotropic Agents Market

  • 29.1. Africa Inotropic Agents Market Overview
  • 29.2. Africa Inotropic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Inotropic Agents Market, Segmentation By Distribution Channel:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Inotropic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Inotropic Agents Market Competitive Landscape And Company Profiles

  • 30.1. Inotropic Agents Market Competitive Landscape
  • 30.2. Inotropic Agents Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. GSK plc
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Mylan N.V.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Boehringer Ingelheim International GmbH
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Inotropic Agents Market Competitive Benchmarking

32. Global Inotropic Agents Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Inotropic Agents Market

34. Inotropic Agents Market Future Outlook and Potential Analysis

  • 34.1 Inotropic Agents Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Inotropic Agents Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Inotropic Agents Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer